Early-Stage Allegro Diagnostics Prepares For Gene Array Market Entry
This article was originally published in The Gray Sheet
Executive Summary
Emerging genetic test firm Allegro Diagnostics is a small fish poised to enter uncertain waters, but the lack of concrete guidelines on FDA regulation of in vitro diagnostic multivariate index assays (IVDMIA) isn't discouraging the company from seeking market entry